Pharm Aid expands portfolio with new focus on women’s health

As part of its ongoing mission to improve access to high‑quality medicines for Russian patients, Pharm Aid announces an expansion of its portfolio and the registration of a new product for women‘s health — Fertigen® (INN: dydrogesterone). The drug is intended for use in gynecological practice, primarily to treat infertility and other conditions associated with progesterone deficiency.

Adding Fertigen® to its portfolio marks the first step in strengthening Pharm Aid’s position in the women’s health segment. The company leverages efforts to save women‘s reproductive health, a key priority of Russia’s state demographic policy and a goal of the national “Family” project.

“Dydrogesterone is globally recognised as the golden standard for treating progesterone‑deficient conditions in reproductive medicine, obstetrics and gynecology,” said Azamat Metov, CEO of Pharm Aid. “Adding Fertigen® to our portfolio completely meets the demand from both healthcare professionals and patients for high‑quality and affordable medicines.”

Fertigen® is anticipated to be available for Russian patients in the nearest future.